Back
Varex Imaging 10K Form
Sell
38
VREX
Varex Imaging
Last Price:
$14.72
Seasonality Move:
-0.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2023-08-01 | 10Q | VREX/Varex Imaging Quarterly |
2023-05-02 | 10Q | VREX/Varex Imaging Quarterly |
2023-01-31 | 10Q | VREX/Varex Imaging Quarterly |
2022-08-03 | 10Q | VREX/Varex Imaging Quarterly |
2022-05-04 | 10Q | VREX/Varex Imaging Quarterly |
2022-02-08 | 10Q | VREX/Varex Imaging Quarterly |
Receive VREX News And Ratings
See the #1 stock for the next 7 days that we like better than VREX
VREX Financial Statistics
Sales & Book Value
Annual Sales: | $811M |
---|---|
Cash Flow: | $19.9M |
Price / Cash Flow: | 28.66 |
Annual Sales: | $13.02 |
Price / Book: | 1.09 |
Profitability
EPS (TTM): | -1.17000 |
---|---|
Net Income (TTM): | $-47.7M |
Gross Margin: | $256.9M |
Return on Equity: | -8.23% |
Return on Assets: | -3.84% |
Varex Imaging Earnings Forecast
Key Varex Imaging Financial Ratios
-
The Gross Profit Margin over the past 12 years for VREX is 31.68%.
-
The Selling, General & Administrative Expenses for VREX have been equal to 16.99% of Gross Profit Margin.
-
The Research & Development expenses have been 10.73% of Revenue.
-
The Interest Expense is -56.18% of Operating Income.
-
The Net Earning history of VREX is -5.88% of Total Revenues.
-
Per Share Earnings over the last 12 years have been positive in 4 years.
Varex Imaging Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Industry: | Health Care Equipment & Supplies |
Sector: | Health Care |
Current Symbol: | VREX |
CUSIP: | 92214X |
Website: | vareximaging.com |
Debt
Debt-to-Equity Ratio: | 0.83 |
---|---|
Current Ratio: | 3.32 |
Quick Ratio: | 1.83 |
Price-to-Earnings
Trailing P/E Ratio: | 11.52 |
---|---|
Forward P/E Ratio: | 15.62 |
VREX Technical Analysis vs Fundamental Analysis
Sell
38
Varex Imaging (VREX)
is a Sell
Is Varex Imaging a Buy or a Sell?
-
Varex Imaging stock is rated a SellThe current Varex Imaging [VREX] share price is $14.71. The Score for VREX is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.